Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Distribution agreement to supply over 200 kg of dried medicinal cannabis flower to Australia

Aether Pacific Pharmaceuticals has secured a distribution agreement with Melbourne-based pharmaceutical supplier Novachem Pty Ltd to provide Aether Pacific's New Zealand-grown medicinal cannabis to the Australian market.

Under the agreement, Aether Pacific will provide cannabis flower to Novachem, which will be finished and packed under Good Manufacturing Practice (GMP) standards into 10-gram jars. The final GMP-grade product will be stored and sponsored by Novachem and provided to patients through Novachem and other distribution pharmacy networks. The end product will be sold under Aether Pacific's 100%-owned subsidiary brand, Medical Kiwi, and can also be white-labeled for other sponsor groups in Australia.

The total shipments to Aether Pacific will make up a total of four different strains grown and cultivated at the company's facility in Christchurch, New Zealand. The facility features advanced technologies and systems for hydroponic growing of carefully selected cultivars for drying of harvest material and export to international markets.

Aether Pacific is confident that the distribution agreement will provide another near-term revenue stream, as well as the potential to expand its footprint into the growing Australian medicinal cannabis market. The company will provide additional updates as the first shipments are completed shortly.

Management commentary
Aether Pacific Pharmaceuticals Chairman, Mr. Aldo Miccio, said: "We are very excited to have secured this distribution agreement with a partner of Novachem's calibre. The group has unparalleled experience in the Australian cannabis industry, and we look forward to leveraging their established distribution network to highlight the benefits of our 100% NZ-grown medicinal cannabis products. The agreement comes at a pivotal time in the company's growth trajectory and will provide near-term revenues ahead of the company's intended listing on the Catalist Public Market."

Novachem Cannabis business manager, Mr. Andrew Heath, said: "It is fantastic to be able to continue to support Medical Kiwi in bringing New Zealand-grown products to market in Australia. The commitment to highest quality cultivation and product development is clearly evident in the products being made available and we are certain that the product will have great support from the medical community."

For more information:
Medical Kiwi
www.medicalkiwi.com

Publication date: